Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. August 2023 07:00 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO,...
24. Mai 2023 08:00 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology to Participate in Upcoming Investor Conferences

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
15. Mai 2023 07:50 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date Preclinical data at AACR Annual Meeting...
15. Mai 2023 07:45 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology Announces $40 Million Underwritten Offering

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced...
20. April 2023 08:00 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
17. April 2023 09:00 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930’s differentiated paralog selectivity and robust repressor activity in...
14. März 2023 07:00 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Focused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025 Novel paralog-selective TEAD inhibitor, IK-930, advanced through multiple dose escalation...
07. März 2023 08:00 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
06. März 2023 08:00 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
28. Februar 2023 08:00 ET | Quelle: Ikena Oncology, Inc.

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...

Vorherige Seite

Nächste Seite